A ceremony was held at the Hanoi Medical University on January 21 to kick-start clinical trials of COVIVAC, Vietnam’s second COVID-19 vaccine candidate and developed based on the new highly-infectious coronavirus variants.
A COVID-19 vaccine developed by the Institute of Vaccines and Medical Biologicals in Khanh Hoa province has returned positive initial results. The institute has therefore proposed the Ministry of Health conduct clinical trials on humans at the end of January.
The highest dose, 75mcg, of Nanocovax, a COVID-19 vaccine developed by Vietnam, was given to three volunteers in Hanoi on January 12 as part of the first stage of human trials.
Vietnam was a bright spot in 2020 for its success in controlling the COVID-19 pandemic, protecting people’s health and maintaining stable economic development in the context of the world struggling to cope with the crisis.
Seventeen more volunteers were injected with Nanocovax, the first COVID-19 vaccine developed by Vietnam, by the Military Medical University in the morning of December 22.
Vietnam is one of the 42 countries able to produce vaccines and among 38 nations to have a vaccine management agency meeting the World Health Organisation (WHO)’s standards.
The IVACFLU-S vaccines, which have been produced in Vietnam to protect against seasonal flu such as A/H1N1, A/H3N2, and B, are now available on the market, according to the Institute of Vaccines and Medical Biologicals under the Ministry of Health.
The IVACFLU-S vaccines, which have been produced in Việt Nam to protect against seasonal flu such as A/H1N1, A/H3N2, and B, are now available on the market, the Institute of Vaccines and Medical Biologicals under the Ministry of Health has said.
Vietnam has produced two vaccines against seasonal and A/H5N1 flu. The vaccines are expected to be licensed by 2019. This makes Vietnam among several countries that have successfully produced A/H5N1
he Institute of Vaccines and Medical Biologicals (IVAC) of Vietnam has announced the successful production of inactivated seasonal influenza vaccine (IVACFLU-S) for commercial use.
Vietnam is expected to produce six-in-one vaccines in 2017 or 2018 and by 2020 these will be used widely in the country, according to the Ministry of Health.
A phase 1 clinical trial of an inactivated influenza A/H5N1 pandemic
vaccine candidate (IVACFLU-H5N1), involving 75 participants in southern
Long An province's Ben Luc district, has so far proven to safely induce
immune responses at various dosage levels in healthy adults.
The Institute for Vaccines and Medical Biologicals under the Health
Ministry is stepping up preparations for production of a vaccine against
H1N1 flu virus in late 2014 or early 2015.
Health
